Blueprint Medicines Stock Price History - Stock Analysis

Oct 25, 2024 · Get a complete stock price history for Blueprint Medicines, starting from its first trading day. Includes open, high, low, close and volume. ... Stock Analysis Pro. Watchlist. …

CouponFollow Extension

$115
OFF

Blueprint Medicines (BPMC) Stock Price, News & Analysis

1 week from now

3 days ago · Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 …

marketbeat.com

2%
OFF

Blueprint Medicines - 9 Year Stock Price History | BPMC

1 week from now

Historical daily share price chart and data for Blueprint Medicines since 2015 adjusted for splits and dividends. The latest closing stock price for Blueprint Medicines as of November 07, 2024 is 101.39.. The all-time high Blueprint Medicines stock closing price was 124.48 on December 23, 2020.; The Blueprint Medicines 52-week high stock price is 121.90, which is 20.2% above the …

macrotrends.net

$128
OFF

Key Takeaways From Blueprint Medicines Analyst Ratings

1 week from now

2 days ago · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $128.0, along with a high estimate of $151.00 and a low …

nasdaq.com

FAQs about Blueprint Medicines Stock Price History - Stock Analysis Coupon?

What is the upside for Blueprint medicines (BPMC) stock?

16 analysts have issued twelve-month price objectives for Blueprint Medicines' stock. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they predict the company's stock price to reach $72.68 in the next year. This suggests a possible upside of 65.2% from the stock's current price. ...

What is the price of BPMC blueprint medicines Corporation (BPMC)?

BPMC Blueprint Medicines Corporation Stock Price & Overview Follow $86.470.86(+1.00%)4:00 PM 10/22/24 NASDAQ |$USD |Post-Market:$86.475:33 PM Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers Options Charting All Analysis Comments News Transcripts SEC Filings Press Releases Related Analysis BPMC Stock Price ...

Is blueprint medicines a good stock to buy?

Blueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and 1 sell rating. According to analysts' consensus price target of $72.68, Blueprint Medicines has a forecasted upside of 66.7% from its current price of $43.61. ...

Who owns blueprint medicines?

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA. If you thought the SVB meltdown was bad… watch out. ...

Where is blueprint medicines headquartered?

The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Trailing total returns as of 10/15/2024, which may include dividends or other distributions. ...

How much does blueprint medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.64 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis. ...